AstraZeneca and Ardelyx have signed a worldwide exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The ...
Tags: RDX5791, Ardelyx, AstraZeneca, NHE3 inhibitor programme, NHE3